Last Posted: Feb 20, 2020
- Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky James et al. JAMA 2020 Feb (7) 646-655 - Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
Frey Melissa K et al. Gynecologic oncology 2020 Feb - [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
Koual Meriem et al. Annales de pathologie 2020 Feb - A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results.
Cortesi Laura et al. Cancer medicine 2020 Feb - Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli Davide et al. International journal of molecular sciences 2020 Feb 21(3) - Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
Seven Memnun et al. Cancer nursing 2020 Jan - Genetic testing in young women with breast cancer: results from a Web-based survey.
Ruddy K J et al. Annals of oncology : official journal of the European Society for Medical Oncology 2010 Apr 21(4) 741-7 - Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
Hao Jing et al. Journal of personalized medicine 2020 Feb 10(1) - Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System.
Richardson Matthew et al. Cancers 2020 Feb 12(2) - Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri Maria Luisa et al. Medicina (Kaunas, Lithuania) 2019 Jul 55(8)
.png)
No hay comentarios:
Publicar un comentario